Are statins an option in the management of abdominal aortic aneurysms?

Vascular and Endovascular Surgery

Volumn 42, Issue 2, 2008, Pages 128-134

  Paraskevas, Kosmas I ^a   Liapis, Christos D ^c   Hamilton, George ^a   Mikhailidis, Dimitri P ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

AAA expansion rate; Abdominal aortic aneurysms; Perioperative mortality; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; MEDLINE; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; RISK REDUCTION; SCREENING;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SCREENING; MICE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RATS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 42249085769     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574407308205     Document Type: Article

References (70)

1. Bengtsson H., Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg. 1993 ; 18: 74-80.
2. Bengtsson H., Bergqvist D., Ekberg O., Janzon L. A population based screening of abdominal aortic aneurysms (AAA). Eur J Vasc Surg. 1991 ; 5: 53-57.
3. Smith FC, Grimshaw GM, Paterson IS, Shearman CP, Hamer JD Ultrasonographic screening for abdominal aortic aneurysm in an urban community. Br J Surg. 1993 ; 80: 1406-1409.
4. Simoni G., Pastorino C., Perrone R., et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg. 1995 ; 10: 207-210.
5. Morris GE, Hubbard CS, Quick CR An abdominal aortic aneurysm screening programme for all males over the age of 50 years. Eur J Vasc Surg. 1994 ; 8: 156-160.
6. Lindholt JS, Henneberg EW, Fasting H., Juul S. Mass or high-risk screening for abdominal aortic aneurysm. Br J Surg. 1997 ; 84: 40-42.
7. Ashton HA, Buxton MJ, Day NE,, et al. Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002 ; 360: 1531-1539.
8. Scott RA, Wilson NM, Ashton HA, Kay DN Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year result of a randomized controlled study. Br J Surg. 1995 ; 82: 1066-1070.
9. Ebaugh JL, Garcia ND, Matsumura JS Screening and surveillance for abdominal aortic aneurysms: who needs it and when. Semin Vasc Surg. 2001 ; 14: 193-199.
10. Brown PM, Zelt DT, Sobolev B. The risk of rupture in untreated aneurysms: the impact of size, gender, and expansion rate. J Vasc Surg. 2003 ; 37: 280-284.
11. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002 ; 346: 1445-1452.
12. Lederle FA, Johnson GR, Wilson SE,, et al. Veterans Affairs Cooperative Study #417 Investigators. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA. 2002 ; 287: 2968-2972.
13. Aziz M., Hill AA, Bourchier R. Four-year follow up of patients with untreated abdominal aortic aneurysms. ANZ J Surg. 2004 ; 74: 935-940.
14. Wilmink TB, Quick CR, Hubbard CS, Day NE The influence of screening on the incidence of ruptured abdominal aortic aneurysms. J Vasc Surg. 1999 ; 30: 203-208.
15. UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998 ; 352: 1649-1655.
16. UK Small Aneurysm Trial Participants. Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998 ; 352: 1656-1660.
17. Buth J., van Marrewijk CJ, Harris PL,, et al. EUROSTAR Collaborators. Outcome of endovascular abdominal aortic aneurysm repair in patients with conditions considered unfit for an open procedure: a report on the EUROSTAR experience. J Vasc Surg. 2002 ; 35: 211-221.
18. Conway KP, Byrne J., Townsend M., Lane IF Prognosis of patients turned down for conventional abdominal aortic aneurysm repair in the endovascular and sonographic era: Szilagyi revisited ? J Vasc Surg. 2001 ; 33: 752-757.
19. Zarins CK, Crabtree T., Arko FR, et al. Endovascular repair or surveillance of patients with small AAA. Eur J Vasc Endovasc Surg. 2005 ; 29: 496-503.
20. Mosorin M., Juvonen J., Biancari F., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001 ; 34: 606-610.
21. Powell JT, Brady AR Detection, management, and prospects for the medical management of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004 ; 24: 241-245.
22. Veith FJ, Tanquilut EM, Ohki T., et al. Conservative observational management with selective delayed repair for large abdominal aortic aneurysms in high risk patients. J Cardiovasc Surg (Torino). 2003 ; 44: 459-464.
23. U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med. 2005 ; 142: 198-202.
24. Lindholt JS, Vammen S., Juul S., Henneberg EW, Fasting H. The validity of ultrasonographic scanning as screening method for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 1999 ; 17: 472-475.
25. Lindholt JS, Henneberg EW, Fasting H. Decreased mortality of abdominal aortic aneurysms in a peripheral country. Eur J Vasc Endovasc Surg. 1995 ; 10: 466-469.
26. Norman PE, Jamrozik K., Lawrence-Brown MM, et al. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004 ; 329: 1259.
27. Lindholt JS, Juul S., Fasting H., Henneberg EW Cost-effectiveness analysis of screening for abdominal aortic aneurysms based on five years results from a randomised hospital based mass screening trial. Eur J Vasc Endovasc Surg. 2006 ; 32: 9-15.
28. Beard JD Screening for abdominal aortic aneurysm. Br J Surg. 2003 ; 90: 515-516.
29. Wanhainen A., Lundkvist J., Bergqvist D., et al. Cost-effectiveness of screening women for abdominal aortic aneurysms. J Vasc Surg. 2006 ; 43: 908-914.
30. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005 ; 21: 231-244.
31. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann Med. 2000 ; 32: 164-176.
32. Koh KK Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability. Cardiovasc Res. 2000 ; 47: 648-657.
33. Tsiara S., Elisaf M., Mikhailidis DP Early vascular benefits of statin therapy. Curr Med Res Opin. 2003 ; 19: 540-556.
34. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005 ; 12: 443-452.
35. Morishita R., Tomita N., Ogihara T. HMG-CoA reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Curr Drug Targets. 2002 ; 3: 379-385.
36. Yildirir A., Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol. 2004 ; 2: 309-318.
37. Auer J., Berent R., Weber T., Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem. 2002 ; 9: 1831-1850.
38. Takemoto M., Liao JK Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1712-1719.
39. Elisaf M., Mikhailidis DP Statins and renal function. Angiology. 2002 ; 53: 493-502.
40. Reddy R., Chahoud G., Mehta JL Modulation of cardiovascular remodeling with statins: fact or fiction ? Curr Vasc Pharmacol. 2005 ; 3: 69-79.
41. Dey S., Mukherjee D. Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular diseases. Curr Vasc Pharmacol. 2003 ; 1: 329-333.
42. Schouten O., Kok NF, Boersma E., et al. Effect of statins on renal function after aortic cross clamping during major vascular surgery. Am J Cardiol. 2006 ; 97: 1383-1385.
43. Goldstein JL, Brown MS Regulation of the mevalonate pathway. Nature. 1990 ; 343: 425-430.
44. Luan Z., Chase AJ, Newby AC Statins inhibit secretion of metalloproteinases-1, -2, -3 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003 ; 23: 769-775.
45. Ikeda U., Shimpo M., Ohki R., et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension. 2000 ; 36: 325-329.
46. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998 ; 18: 1671-1678.
47. Wong B., Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol. 2001 ; 69: 959-962.
48. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002 ; 36: 158-163.
49. Ejiri J., Inoue N., Tsukube T., et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res. 2003 ; 59: 988-996.
50. Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003 ; 26: 618-622.
51. Steinmetz EF, Buckley C., Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005 ; 241: 92-101.
52. Kalyanasundaram A., Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg. 2006 ; 43: 117-124.
53. Sukhija R., Aronow WS, Sandhu R., Kakar P., Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with or without statins. Am J Cardiol. 2006 ; 97: 279-280.
54. Schouten O., van Laanen JH, Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006 ; 32: 21-26.
55. Wilson WR, Evans J., Bell PR, Thompson MM HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2005 ; 30: 259-262.
56. Evans J., Powell JT, Schwalbe E., Loftus IM, Thompson MM Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ; 34: 302-303.
57. Rigberg DA, Zingmond DS, McGory ML, et al. Age stratified, perioperative, and one-year mortality after abdominal aortic aneurysm repair: a statewide experience. J Vasc Surg. 2006 ; 43: 224-229.
58. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
59. Lloyd GM, Newton JD, Norwood MG, Franks SC, Bown MJ, Sayers RD Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction ? J Vasc Surg. 2004 ; 40: 691-697.
60. Schouten O., Kok NF, Hoedt MT, van Laanen JH, Poldermans D. The influence of aneurysm size on perioperative cardiac outcome in elective open infrarenal aortic aneurysm repair. J Vasc Surg. 2006 ; 44: 435-441.
61. Schouten O., van Waning VH, Kertai MD, et al. Perioperative and long-term cardiovascular outcomes in patients undergoing endovascular treatment compared with open vascular surgery for abdominal aortic aneurysm or iliaco-femoro- popliteal bypass. Am J Cardiol. 2005 ; 96: 861-866.
62. Mason JM, Wakeman AP, Drummond MF, Crump BJ Population screening for abdominal aortic aneurysm: do the benefits outweigh the costs ? J Public Health Med. 1993 ; 15: 154-160.
63. Paraskevas KI, Liapis CD, Hamilton G., Mikhailidis DP Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery ? Eur J Vasc Endovasc Surg. 2006 ; 32: 286-293.
64. Kertai MD, Boersma E., Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg. 2004 ; 28: 343-352.
65. Leurs LJ, Visser P., Laheij RJ, Buth J., Harris PL, Blankensteijn JD Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular. 2006 ; 14: 1-8.
66. Kertai MD, Boersma E., Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med. 2004 ; 116: 96-103.
67. British National Formulary. March 2007 ; v53. BMJ Publishing Group ; 2007. Available at: http://www.bnf.org/bnf/bnf/current/128043.htm. Accessed June 2007.
68. RxUSA New York State Registered Pharmacy, March 2007. Available at http://rxusa.com/. Accessed June 2007.
69. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006 ; 26: 2605-2613.
70. Dawson J., Choke E., Sayed S., Cockerill G., Loftus I., Thompson MM Pharmacotherapy of abdominal aortic aneurysms. Curr Vasc Pharmacol. 2006 ; 4: 129-149.